The federal Project Grant award of $1,782,155.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Mayo Clinic to identify novel drug targets for lethal prostate cancer using liquid biopsy. The award, effective from April 1, 2025, to March 31, 2028, will enable Mayo Clinic to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public. This...
The federal Project Grant award of $161,400.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research project titled "AN ATLAS OF THE TUMOR IMMUNE CIRCULOME." This award, with a performance period from June 1, 2024 to May 31, 2025, aims to advance medical knowledge and improve patient care through innovative biomedical research. The Military Medical Research and Development program funds a wide range of...
The U.S. Defense Health Agency awarded a $2,124,536 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Mayo Clinic to conduct a clinical evaluation of combination immunotherapy for renal cell carcinoma (RCC). This 3-year project, running from August 2024 to August 2027, will leverage Mayo Clinic's expertise in cancer research and drug development to advance promising immunotherapies for treating RCC. The award will support preclinical pharmacokinetic and...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
Mayo Clinic will receive $795,000 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct the project "PHARMACODYNAMIC BIOMARKER-GUIDED METABOLIC COLLAPSE OF IDH-MUTANT GLIOMA" from September 2021 through September 2024. This Project Grant aims to develop medical solutions for the battlefield by investigating pharmacodynamic biomarkers to guide targeted metabolic therapies for the treatment of isocitrate...
The Mayo Clinic received a $278,250 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from August 2021 through July 2025 to develop techniques for cytokine modulation of chimeric antigen receptor T cells to increase their safety and efficacy. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions...
The U.S. Defense Health Agency has awarded a $1,187,875 Project Grant to Mayo Clinic to support the research project "INVESTIGATING MOLECULAR MECHANISMS UNDERLYING THE CILIARY TRAFFICKING OF POLYCYSTINS". This grant, awarded on April 1, 2024 under the Military Medical Research and Development program (CFDA 12.420), will fund research to advance the understanding of the molecular mechanisms involved in the trafficking of polycystins through cellular cilia. The project aims to yield...
Mayo Clinic was awarded a $8,966,819 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from July 1, 2023 to June 30, 2027 to further develop purified exosome products for treating pulmonary damage from toxic exposures, leveraging Mayo Clinic's expertise in exosome applications. Through this funding, Mayo Clinic aims to advance biomedical solutions applicable to both military and civilian...
The Department of Defense's Defense Health Agency awarded a $322,800 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Mayo Clinic in Rochester, Minnesota. The grant, with a performance period from April 1, 2024 to March 31, 2026, supports research on "MYELOPEROXIDASE PROMOTES PERSISTENT FIBROSIS." As a renowned non-profit academic medical center, Mayo Clinic will leverage its expertise in clinical care, biomedical research, and medical...
The Mayo Clinic was awarded a $1.7 million project grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will support research from August 2021 through July 2025 to develop techniques for cytokine modulation of chimeric antigen receptor T cells to increase their safety and efficacy. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research...